Development Partners International (DPI) is pleased to announce the close of its exit from KELIX bio. The transaction is one of the largest private equity exits and M&A deals in Africa’s pharmaceutical sector over the past twenty years.
DPI created KELIX bio alongside management and co-investors British International Investment and EBRD in 2020. Since then, it has grown rapidly and now exports critical medicines to over 50 countries across Africa, Latin America, Southeast Asia and the Middle East.
The additional backing of global Development Finance Institutions Proparco, DEG, and FMO - Dutch entrepreneurial development bank also enabled KELIX bio’s rapid growth into new markets and ultimately broadened access to vital specialty generic drugs across emerging markets globally.
DPI wishes KELIX bio and its leadership team and new owners the best of success, and we look forward to seeing the firm continue to deliver lifesaving treatments to the markets where they are most needed.